Core Viewpoint - A class action lawsuit has been filed against Altimmune Inc. by Berger Montague on behalf of investors who acquired the company's securities during the specified class period from August 10, 2023, to June 25, 2025 [1][2]. Company Overview - Altimmune Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [2]. Legal Action Details - Investors who purchased Altimmune securities during the class period have until October 6, 2025, to seek appointment as lead plaintiff representatives [2]. - The lawsuit follows a press release from Altimmune on June 26, 2025, announcing disappointing results from its IMPACT Phase 2b trial of Pemvidutide for MASH treatment, where the primary endpoint of fibrosis reduction did not achieve statistical significance [3]. Stock Price Impact - Following the announcement of the trial results, Altimmune's stock price plummeted by 53.2% in one day, dropping from a closing price of $7.71 on June 25, 2025, to $3.61 on June 26, 2025 [4].

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against KinderCare Learning Companies, Inc. following a class action lawsuit related to undisclosed safety and compliance failures at its facilities [1][3]. Group 1: Company Overview - KinderCare Learning Companies, Inc. is a national operator of early childhood education centers, headquartered in Portland, Oregon [2]. Group 2: Legal Proceedings - A securities class action lawsuit has been filed on behalf of investors who purchased KinderCare securities between October 6, 2024, and August 12, 2025, including during the Company's initial public offering in October 2024 [1][2]. - Investors have until October 14, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 3: Allegations and Impact - The investigation focuses on allegations that KinderCare failed to disclose incidents of child abuse, neglect, and harm at its centers, leading to a significant decline in stock value [3]. - At the time the lawsuit was filed, KinderCare's stock had dropped to approximately $9 per share, representing a loss of about 60% from its IPO value [3].

Group 1 - The core issue involves a securities fraud investigation against Spectrum Pharmaceuticals, initiated by Berger Montague on behalf of investors who acquired shares between March 17, 2022, and September 22, 2022 [1][2] - The class action lawsuit claims that Spectrum made false or misleading statements regarding its Pinnacle Study, which is a clinical trial for the drug poziotinib aimed at treating certain lung cancer patients [3] - Following a merger with Assertio Holdings, Spectrum's shares were delisted, raising concerns among investors [3] Group 2 - Investors have a deadline of September 24, 2025, to seek appointment as lead plaintiff representative in the class action [2] - Berger Montague has a long history in securities class action litigation, having represented investors for over five decades [5]

Core Viewpoint - Berger Montague PC is investigating claims against CTO Realty Growth, Inc. for allegedly misleading investors regarding its financial condition and manipulating key metrics [1][2] Group 1: Legal Investigation - The investigation pertains to claims under federal securities laws against CTO Realty Growth, a real estate investment trust based in Winter Park, Florida [1] - Investors who acquired CTO securities between February 18, 2021, and June 24, 2025, have until October 7, 2025, to seek appointment as lead plaintiff [2] Group 2: Allegations and Financial Misconduct - The lawsuit alleges that CTO misled investors by overstating the profitability of properties, including Ashford Lane in Atlanta [2] - A report by Wolfpack Research accused CTO of covering a $38 million dividend shortfall by diluting shareholders, increasing the outstanding share count by 70% [3] - The report also claimed CTO used a "sham loan" to conceal issues with a collapsed tenant at Ashford Lane [3] Group 3: Market Reaction - Following the allegations, CTO's stock experienced a 5.42% decline, closing at $17.10 per share on June 25, 2025 [3]

Group 1 - A class action lawsuit has been filed against KinderCare Learning Companies, Inc. on behalf of investors who purchased shares during the period from October 6, 2024, to August 12, 2025, including its October 2024 IPO [1][2] - The lawsuit alleges that the IPO registration statement contained false and misleading statements, failing to disclose incidents of child abuse, neglect, and harm at KinderCare facilities, and that the company did not meet minimum care standards [3] - Since the IPO, KinderCare's shares have significantly declined, reaching lows near $9 per share, resulting in substantial losses for investors [4] Group 2 - Investors who acquired KinderCare securities during the class period have until October 14, 2025, to seek appointment as lead plaintiff representative of the class [2] - Berger Montague, the law firm representing the plaintiffs, has a long history in securities class action litigation, having represented investors for over five decades [5]

Group 1 - The law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. on behalf of investors who acquired shares between March 17, 2022, and September 22, 2022 [1][2] - The class action lawsuit alleges that Spectrum made false or misleading statements regarding its Pinnacle Study, a clinical trial for the drug poziotinib, which is intended for lung cancer treatment [3] - Spectrum shares were delisted following the merger with Assertio Holdings, Inc. [3] Group 2 - Investors have until September 24, 2025, to seek appointment as lead plaintiff representative of the class [2] - Berger Montague has a long history in securities class action litigation, having represented investors for over five decades [5]

Core Viewpoint - Berger Montague PC is investigating claims against Novo Nordisk A/S following a class action lawsuit related to the company's lowered sales and profit guidance for the second half of fiscal 2025 [1][3]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk lowered its sales and profit guidance for the second half of fiscal 2025, attributing this to persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® [3]. - Following the announcement, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Group 2: Legal Actions - A class action lawsuit has been filed against Novo Nordisk, and investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, may seek to be appointed as lead plaintiff representatives by September 30, 2025 [2].

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against CTO Realty Growth, Inc. following a class action lawsuit related to securities purchased between February 18, 2021, and June 24, 2025 [1][2] Company Overview - CTO Realty Growth, Inc. is a real estate investment trust (REIT) headquartered in Winter Park, Florida [2] Legal Allegations - The lawsuit alleges that on June 25, 2025, Wolfpack Research published a report accusing CTO of financial manipulation, claiming the company covered a $38 million dividend gap by significantly diluting its shares and excluding necessary recurring capital expenditures from its Adjusted Funds From Operations [3] - The report also alleged that CTO used a "sham loan" to conceal a major tenant failure at Ashford Lane, a key property [3] Market Reaction - Following the allegations, CTO's stock price fell nearly 6%, closing at $17.10 per share on June 25, 2025 [4]

Group 1 - A class action lawsuit has been filed against Altimmune Inc. on behalf of investors who acquired its securities between August 10, 2023, and June 25, 2025 [1][2] - The lawsuit follows the announcement of disappointing results from the IMPACT Phase 2b trial of Pemvidutide for treating MASH, where the primary endpoint of fibrosis reduction did not achieve statistical significance [3] - Following the trial results announcement, Altimmune's stock price plummeted by 53.2%, closing at $3.61 on June 26, 2025, down from $7.71 the previous day [4] Group 2 - Altimmune is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH [2] - The company had previously made positive statements regarding the trial results, which ultimately did not materialize as expected [3]

Core Viewpoint - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. for misleading statements made during the Class Period from March 17, 2022, to September 22, 2022 [1][3] Company Overview - Spectrum Pharmaceuticals is a biopharmaceutical company focused on oncology treatments [2] Legal Proceedings - A class action lawsuit has been filed alleging that Spectrum made false or misleading statements regarding its Pinnacle Study, which involved the drug poziotinib for lung cancer treatment [3] - Investors who acquired Spectrum securities during the Class Period have until September 24, 2025, to seek appointment as lead plaintiff representative [2] Company Actions - Spectrum shares were delisted following the merger with Assertio Holdings, Inc. [3]